Product innovations, and excellence in trade relations practices are honored
At HDMA’s 2011 Business & Leadership Conference (Phoenix, AZ, June 6-7), the association presented Distribution Awards for Notable Achievement in Healthcare (DIANA), which are selected by HDMA’s distributor members. Now in its 50th year, the DIANA recognizes innovative new product introductions, and “business practices that advance trade relations and benefit the entire healthcare supply chain.” The awards are:
Best New Pharmaceutical Product Introduction or Product Promotion Awards
Branded Pharmaceutical Products: Boehringer Ingelheim Pharmaceuticals, Inc., for Pradaxa®
Generic Pharmaceutical Products: Sandoz, for Enoxaparin
Best Overall Manufacturer Awards
Consumer Product Manufacturer with Sales to Healthcare Distributors of Less Than $10 Million:
Winner: Omron Healthcare, Inc.
First Merit Finalist: Broadway Industries
Consumer Product Manufacturer with Sales to Healthcare Distributors of More Than $10 Million:
Winner: Roche Diagnostics Corporation
First Merit Finalists: Amneal Pharmaceuticals LLC and Reckitt Benckiser Group
Second Merit Finalist: Novartis Consumer Health, Inc.
Generic Product Manufacturer with Sales to Healthcare Distributors of Less Than $100 Million:
Winner: Lupin Pharmaceuticals, Inc.
First Merit Finalist: Lannett Company, Inc.
Second Merit Finalist: Paddock Laboratories, Inc.
Generic Product Manufacturer with Sales to Healthcare Distributors of More Than $100 Million:
Winner: Watson Pharmaceuticals, Inc.
First Merit Finalist: Dr. Reddy’s Laboratories, Inc.
Second Merit Finalist: Amneal Pharmaceuticals LLC
Branded Pharmaceutical Product Manufacturer with Sales to Healthcare Distributors of Less Than $300 Million:
Winner: Upsher-Smith Laboratories, Inc.
First Merit Finalist: Amylin Pharmaceuticals, Inc.
Second Merit Finalist: Kerr Prescription Packaging, a Subsidiary of Berry Plastics Corp.
Branded Pharmaceutical Product Manufacturer with Sales to Healthcare Distributors of More Than $300 Million:
Winner: Takeda Pharmaceuticals North America, Inc.
First Merit Finalist: Bayer HealthCare Pharmaceuticals Inc.
Second Merit Finalist: Forest Pharmaceuticals, Inc.
According to HDMA, winners for Best Overall Manufacturer were chosen on criteria ranging from developing collaborative trading partner relationships to creating marketing programs that benefit the supply chain and commitment to excellence. Among other criteria, the Best New Product Introduction or Promotion winners were judged on their ability to create innovative marketing programs, their level of market performance, promotional support and operational excellence.
“The 2011 DIANA honorees set the standard for excellence in the healthcare supply chain, introducing innovative new products to the marketplace and forging lasting partnerships with their peers in the healthcare distribution industry,” said HDMA president John M. Gray. “These winning companies lead the way with their continuing commitment to creativity and collaboration, and we congratulate them on their achievements.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.